2 of (poly(pentafluorophenyl acrylate) (pPFPA) and pBA were first prepared by RAFT polymerization followed by post-polymerization functionalization with aminoethyl glycosides to yield p(NβGlcEAM-b-BA) and p(NβGalEAM-b-BA) which were then used to form glyco-NPs (glucosylated and galactosylated NPs, Glc-NPs and Gal-NPs, respectively). The glyco-NPs were characterized by dynamic light scattering (DLS) and TEM. Encapsulation and release of ampicillin, leading to nanoparticles that we have termed 'glyconanobiotics', were studied. The ampicillin-loaded glyco-NPs were found to induce aggregation of Staphylococcus aureus and Escherichia coli and resulted in antibacterial activity approaching that of ampicillin itself. This glyconanobiotics strategy represents a potential new approach for the delivery of antibiotics close to the surface of bacteria by promoting bacterial aggregation. Defined release in the proximity of the bacterial envelope may thus enhance antibacterial efficiency and potentially reduce the quantities of agent required for potency.
Over the last century, morbidity and mortality as a consequence of infectious diseases have decreased drastically, due to the wide-spread development and deployment of vaccines and antimicrobial agents. 1 However, bacterial resistance to our available antibiotic repertoire is now reaching a critical level, potentially bringing about a post-antibiotic era. 2 Considerable effort has been expended to overcome this problem through the discovery of new antibiotics and chemical modification of existing antibacterial drugs. Nevertheless, the development of new antimicrobial drugs is unlikely to outpace the emergence of microbial pathogen resistance. The continued evolution of antimicrobial resistance mechanisms has prompted the scientific community to seek longer-term solutions to this ever-growing problem. 3 Metallic nanomaterials (e.g. Ag, Au, and Cu) have been found to display strong antimicrobial properties. 4 Nevertheless, their applications as antimicrobial agents are limited by their potential toxicity to human cells as a result of their unusual physicochemical properties and/or physical or chemical production techniques.
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Encapsulation or conjugation of antibiotics into different classes of nanocarriers has been recently represented as a potential approach to combat infectious diseases. [6] [7] [8] This approach can not only offer efficient intracellular delivery to pathogens but also help in controlling the amount and frequency of drug dosage and hence reduces the toxicity associated to therapy and may overcome bacterial resistance.
Strategies that do not kill the pathogens yet interfere with their pathogenic mechanisms may provide a promising alternative. One such strategy is anti-adhesion therapy, which interferes with the early stages of infection in which pathogens attach to the mammalian cell surface. [9] [10] [11] This adhesion is often mediated by protein-carbohydrate interactions: proteins on the pathogen binding to displayed carbohydrate structures or receptors on the eukaryotic cell. These interactions are often highly specific and determine the preference of the pathogen for certain 4 tissue types, known as tropism. Free carbohydrates can be harnessed to interfere with bacterial attachment, thus preventing initial colonization and subsequent infection. This principle is operative daily as part of the innate immune system, for example human breast milk contains many oligosaccharides that act as anti-adhesives. 12 However, the limited affinity of monovalent carbohydrates for target proteins that are often multivalent hinders the application of this approach. Therefore, designing multivalent glycosylated constructs that can inhibit proteincarbohydrate interactions may be productive in finding a way forward.
During the last decade, nanoparticles presenting carbohydrate/glycan functionalities at their surfaces have been reported to exhibit antibacterial actions towards different classes of bacteria including Gram-positive, Gram-negative and mycobacteria [ref] . Most of these reports focused on using nanoparticles with an inorganic core, such as gold, silver, iron oxide, silica, copper, bismuth, palladium, and platinum. 13 A major reason for the special interest in these inorganic materials is their attractive physical properties, such as plasmonic effects, luminescence and/or magnetic susceptibility which make them especially useful for both imaging and therapeutic (theranostic) applications. One of the most studied examples of carbohydrate-mediated targeting that leads to bacterial growth inhibition exerted by aggregation has been shown with mannosylated silver and gold nanoparticles, interacting with fimbriated E. coli strains. 14, 15 Bacterial growth inhibition has also been demonstrated with non-targeting glycosylated nanoparticles, where the carbohydrate moieties serve as stabilising and/or solubilizing agents.
For example, silver nanoparticles functionalized with kocuran (an exopolysaccharide produced by Kocuria rosea strain BS-1) were probed against a range of bacterial strains, of which S.
aureus was affected the most. 16 The binding affinity and specificity of glycosylated nanoparticles to many bacterial strains is not well-studied in the literature and needs further attention.
Here, we report the construction of polymeric glycosylated nanoparticles (glyco-NPs) that encapsulate an antibiotic (ampicillin) as an amalgamated system, which we refer to as glyconanobiotics. Our hypothesis is that antibiotic delivery will be enhanced if the nanoparticle delivery vehicle is capable of binding to, and aggregating, the bacteria, and therefore releasing the antibiotic in the proximity of the bacterial surface. As an example, the pili of E. coli contain at their tips the FimH protein which has binding specificity for glucose and mannose. 17 Consequently, multivalent glucosylated nanoparticles loaded with antibacterial agent could form such a glyconanobiotic delivery system. Ampicillin was used in this study as a wellcharacterized and potent antibiotic. It is a semi-synthetic derivative of penicillin, with a relatively short-term stability in aqueous solutions. 18 It is used clinically for the treatment of a broad range of bacterial infections. 19, 20 Improvement of its activity and reduction of its allergic and toxic reactions have been achieved by means of topical formulations 21 and the use of liposomal nanoparticles as passive delivery systems. 22, 23 Moreover, from the pharmaceutical application perspective, these liposomal nano-carriers provide endocytozable formulations for intracellular chemotherapy, since β-lactam antibiotics do not diffuse readily through the lysosomal membrane because of their ionic character at neutral extracellular or cytoplasmatic pH. 24 Polymeric nanoparticles offer, over liposomes, certain advantageous features with respect to chemical and biological stability and prolonged circulation times in the bloodstream. 25 Furthermore, they can be prepared in such a way that they present on their external surface biologically active functionalities, 26, 27 for example carbohydrates as employed in this study.
EXPERIMENTAL METHODS

Typical synthesis of amphiphilic glycopolymers
6 PFPA (476 mg, 2 mmol), benzyl 2-hydroxyethyl carbonotrithioate (32 mg, 0.13 mmol), AIBN (4.5 mg, 0.025 mmol) and benzene (5 mL) were placed into a Schlenk flask equipped with a stirrer bar. After degassing by purging with nitrogen under an ice bath for 30 min, the solution was heated to 70 °C and stirred for 6 h. Conversion of monomer to polymer was determined by
In vitro drug release from ampicillin-loaded glyco-NPs
Ampicillin-encapsulated glyco-NPs were prepared using the nanoprecipitation method with the addition of 0.5 mg of ampicillin to the organic phase. Samples with a specific amount of ampicillin-encapsulated glyco-NP suspensions were subjected to high-speed centrifugation of 10,000 rpm for 30 min. The supernatant containing the unencapsulated ampicillin was isolated.
The ampicillin content in the supernatant was assayed by HPLC and the encapsulation efficiency (EE) was calculated. Full details are given in the Supporting Information file.
Turbidimetric Assay
Concanavalin A (Con A) was dissolved in HBS buffer (10 mM HEPES, 90 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1 mM MnCl2, pH = 7.4) (1 mg/mL), and the resulting solution was gently mixed. Turbidity measurements were performed by adding the Con A solution (400 µL) to a dry quartz cuvette (500 µL volume, 1 cm path length). A solution of the glyco-NP of interest in HBS buffer (prepared by nanoprecipitation method as described above) was then added (100 µL at 2 mg/mL). Upon addition, the solution was mixed vigorously using a micropipette before placement in a Varian Cary-100 UV-Vis spectrophotometer. Absorbance data were recorded at 420 nm for 10 min.
Bacteriological experiments
The bacteriological studies of the glyco-NPs (both Glc-NPs and Gal-NPs) and the ampicillin loaded glyco-NPs were investigated using an 
RESULTS AND DISCUSSION
We designed amphiphilic glycopolymers with different compositions (hydrophilic to hydrophobic block ratio) that could assemble in aqueous solution, using the nanoprecipitation method, 28, 29 into NPs with sugar moieties presented on the surface. Our synthetic approach was based on the reversible addition fragmentation chain transfer (RAFT) polymerization of an activated ester, pentafluorophenyl acrylate (PFPA), followed by chain extension using n-butyl acrylate (BA) for subsequent modification with aminoethyl glycosides (Fig. 1A) . We first polymerized PFPA using benzyl 2-hydroxyethyl carbonotrithioate (BHECTT) as a chain transfer agent. The resulting pPFPA macroRAFT agents were then used to polymerize BA to generate block copolymers with different compositions as revealed by 1 H-NMR spectroscopy (Fig. S1 , supporting information). After purification by reprecipitation, the block copolymers were analyzed by SEC which showed monomodal distributions with dispersities of about ca. FTIR spectroscopy were achieved (Fig. S2-4, supporting information) . The final glycopolymers were characterized by SEC as shown in Table S1 (supporting information).
Glyco-NPs were prepared via the nanoprecipitation method and characterized by determining their diameter, external morphology and ampicillin encapsulation efficiency. The results showed that as the DP of the hydrophobic segment (pBA) increases, the diameter of the obtained NPs also increases (Table 1) . Glucopolymer p(NβGlcEAM15-b-BA120) was found to form the largest NPs with a diameter of 272 ± 14 nm by DLS, Table 1 . In addition, TEM was used to explore the morphology of the NPs. The obtained NPs are roughly spherical in shape; the apparent diameter of the NPs by TEM was found to be higher than their diameter in the hydrated state, most probably because of their flattened structure (Fig. 1B and 1F ). Encapsulation of ampicillin led to a small increase in NP diameter (Table 1 , entries 4 and 5). We therefore employed NPs made from glycopolymer p(NβGlcEAM15-b-BA120) in this study which showed the largest diameter and were expected to possess the highest drug loading capacity. The ampicillin encapsulation efficiency (EE) of these NPs was found to be 47 %. The typical in vitro release profile of a drug from NPs often displays two distinct regions; an early, rapid release, while the remainder is liberated slowly during an extended period of time.
The early release represents the loss of surface-associated and poorly entrapped drug. The magnitude of this burst effect is dependent on the quantity of drug bound to the outer surface of the NPs. However, the drug release from within the NP core is controlled by diffusion. 30 In our case, the percentage cumulative ampicillin release versus time plot did not show an initial burst release phase. Instead, slow and constant zero-order ampicillin release kinetics was observed.
The cumulative ampicillin release from NPs after 21 days was found to be 56 % (Fig. 2) . The ability of the glycosylated NPs to bind to the glucose/mannose specific lectin Concanavalin-A (Con-A) was evaluated using a well-established turbidimetric assay. 31 In this assay, the Con-A tetramer is mixed with an excess of the multivalent ligand under investigation, inducing rapid precipitation. The change in turbidity is related directly to the formation of Con-A clusters in solution mediated by the appropriate multivalent ligand. The glucose-containing NPs were found to bind readily to Con-A; however, galactose-containing NPs did not show any binding affinity ( 
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We performed bacterial minimal inhibitory concentration (MIC) assays 32 using both glucosylated and galactosylated NPs (Glc-NPs and Gal-NPs, respectively), ampicillin loaded Glc-NPs and free ampicillin against representative Gram-positive (Staphylococcus aureus and
Staphylococcus epidermidis) and Gram-negative (Escherichia coli) bacteria. Unloaded Glc-NPs and Gal-NPs showed no significant antibacterial activity against these bacterial species (Fig. 4A-C ), although there was some indication of a reduction in growth in the 5-25 µg/ml concentration range for Glc-NPs mixed with E. coli (Fig. 4A ). Visual inspection of the plates revealed that this is due to aggregation of E. coli correlating with an increased Glc-NP concentration ( Fig. 4D and also evident in the increased absorbance at the highest Gal-NP concentrations in Fig. 4A ) (no aggregation was evident in any other wells). Carbohydrate recognition sites have been identified on the pili of E. coli. The FimH protein, present in the W3110 strain used here 33 which is exposed at the tip of the pili, has binding specificity for glucose and mannose on human cell surfaces 17 and so this is a likely explanation for the E. coli aggregation observed with Glc-NPs but not with the non-binding Gal-NPs. The affinity of FimH for galactose is 10-fold lower than that for glucose in a surface plasmon resonance assay 34 . 
epidermidis.
Both ampicillin-loaded Glc-NPs and free ampicillin show antibacterial activity against E. coli, S. aureus and S. epidermidis (Fig. 5B-D) . The MIC values of ampicillin loaded Glc-NPs and free ampicillin against different bacterial strains are shown in Table 2 . Ampicillin-loaded Glc-NPs exhibited MICs 4-fold and 2-fold higher than free ampicillin against the Gram-negative strain E.
coli and Gram-positive strains S. epidermidis and S. aureus, respectively. This presumably reflects the slower release of ampicillin from the Glc-NPs, compared to free ampicillin. The extent of bacterial killing is nonetheless quite remarkable given the small amount of ampicillin (Fig. 2) . The Glc-NPs alone display some antibacterial effect even without encapsulation of ampicillin, the reason for which requires further investigation. We also investigated bacterial morphology and aggregation in the presence or absence of GlcNPs using TEM ( Fig. 6A and 6B ). The bacterial cultures were dried onto TEM grids, stained with uranyl acetate, and imaged using TEM. The resulting micrographs confirm that bacteria in the presence of Glc-NPs form significantly more aggregates compared to the control experiment without addition of Glc-NPs. Indeed, these TEM micrographs are representative of each sample as indicated by the collected statistical data ( Fig. 6C and 6D ). We refer to any cluster of ten or more cells attached to each other as "aggregated"; fewer than ten associated cells was defined as "unaggregated". Based on this collected data, we noted a marked increase in the aggregation percent of E. coli cells in the presence of Glc-NPs compared to the control experiment without Glc-NPs (Fig. 6C ). This was also the case for S. aureus cells ( 
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